Skip to main content
Terug
SNDX logo

Syndax Pharmaceuticals, Inc.

Datakwaliteit: 100%
SNDX
NASDAQ Healthcare Biotechnology
€ 24,09
▼ € 0,14 (-0,58%)
Marktkapitalisatie: 2,12B
Dagbereik
€ 23,99 € 25,00
52-Weeksbereik
€ 8,58 € 25,44
Volume
883.520
50D / 200D Gem.
€ 21,50 / € 16,47
Vorige Slotkoers
€ 24,23

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -7,4 0,4
P/B 32,9 2,9
ROE % -161,8 3,8
Net Margin % -165,6 3,9
Rev Growth 5Y % 5,4 10,0
D/E 5,4 0,2

Belangrijkste Punten

Revenue grew 5,39% annually over 5 years — modest growth
Debt/Equity of 5,36 — high leverage
Negative free cash flow of -323,17M
PEG of 0,55 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 622,45%
Capital efficient — spends only 0,11% of revenue on capex

Groei

Revenue Growth (5Y)
5,39%
Revenue (1Y)627,84%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-161,82%
ROIC-49,82%
Net Margin-165,60%
Op. Margin-158,45%

Veiligheid

Debt / Equity
5,36
Current Ratio4,40
Interest Coverage-8,08

Waardering

P/E Ratio
-7,44
P/B Ratio32,88
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 627,84% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5,39% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 172,35M Net Income (TTM) -285,42M
ROE -161,82% ROA -53,88%
Gross Margin 95,96% Operating Margin -158,45%
Net Margin -165,60% Free Cash Flow (TTM) -323,17M
ROIC -49,82% FCF Growth (3Y) N/A
Safety
Debt / Equity 5,36 Current Ratio 4,40
Interest Coverage -8,08 Dividend Yield 0,00%
Valuation
P/E Ratio -7,44 P/B Ratio 32,88
P/S Ratio 12,33 PEG Ratio 0,55
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,12B Enterprise Value 2,34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 172,35M 23,68M 0,0 0,0 139,71M
Net Income -285,42M -318,76M -209,36M -149,34M 24,93M
EPS (Diluted) -3,30 -3,73 -2,98 -2,46 0,48
Gross Profit 165,38M 22,85M 0,0 0,0 139,71M
Operating Income -273,08M -339,67M -229,95M -151,76M 26,22M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 529,71M 724,82M 612,88M 497,24M 449,66M
Total Liabilities 465,08M 436,69M 58,68M 29,79M 41,29M
Shareholders' Equity 64,63M 288,12M 554,20M 467,45M 408,37M
Total Debt 346,48M 345,74M 1,64M 1,16M 20,97M
Cash & Equivalents 134,93M 154,08M 295,39M 74,36M 221,97M
Current Assets 528,08M 603,06M 580,88M 489,79M 448,40M
Current Liabilities 120,12M 103,55M 58,10M 29,07M 20,68M